Wells Fargo & Company Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $700.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective decreased by Wells Fargo & Company from $750.00 to $700.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective decreased by Wells Fargo & Company from $750.00 to $700.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the […]
